0
0

Safe Medicine Act

2/9/2022, 3:26 AM

Congressional Summary of HR 5982

Safe Medicine Act

This bill authorizes the Food and Drug Administration to temporarily ban the sale of a drug if (1) the drug (or an active ingredient of the drug) is manufactured in a country that, because of systemic problems of supervision, may be producing contaminated drugs; and (2) the drug's labeling does not have certain warnings about potential contamination.

The bill also requires the Department of Health and Human Services to report to Congress on vulnerabilities in the U.S. medicine supply chain, including vulnerabilities related to reliance on production from other countries.

Current Status of Bill HR 5982

Bill HR 5982 is currently in the status of Bill Introduced since February 26, 2020. Bill HR 5982 was introduced during Congress 116 and was introduced to the House on February 26, 2020.  Bill HR 5982's most recent activity was Referred to the House Committee on Energy and Commerce. as of February 26, 2020

Bipartisan Support of Bill HR 5982

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
3
Democrat Cosponsors
1
Republican Cosponsors
2
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 5982

Primary Policy Focus

Health

Potential Impact Areas

- Administrative law and regulatory procedures
- Asia
- China
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- Government studies and investigations
- Health care costs and insurance
- Health information and medical records
- Health technology, devices, supplies
- Manufacturing
- Prescription drugs
- Public contracts and procurement
- Trade restrictions

Alternate Title(s) of Bill HR 5982

Safe Medicine Act
To direct the Secretary of Health and Human Services to study American dependence on Chinese pharmaceuticals and to empower the Food and Drug Administration to issue boxed warnings in the case of critical contamination.
Safe Medicine Act

Comments